Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, Butler MO, Cheng T, Romano PM, Pons-Tostivint E, Di Nicola M, Curigliano G, Ryu MH, Rodriguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R.
Robbrecht D, et al. Among authors: cheng t.
Clin Transl Sci. 2024 Feb;17(2):e13736. doi: 10.1111/cts.13736.
Clin Transl Sci. 2024.
PMID: 38362837
Free PMC article.
Clinical Trial.